ACRS•benzinga•
Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrades Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 18, 2024 by benzinga